MedTrace Logo

Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening

NCT07195071 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-02-18

No results posted yet for this study

Summary

The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention

Conditions

  • Hereditary Cancer Syndrome

Interventions

DEVICE

Natera empower comprehensive hereditary cancer panel

Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers

DEVICE

Obstetrical carrier screening

Obstetrical carrier screening for genetic conditions

Sponsors & Collaborators

Principal Investigators

  • Shayan Dioun, MD · Columbia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07195071 on ClinicalTrials.gov